Document is current
Any future updates will be listed below
-
Authors
Peralta, Ronal M.
Xie, Bingxian
Lontos, Konstantinos
Nieves-Rosado, Hector
Spahr, Kellie
Joshi, Supriya
Ford, B. Rhodes
Quann, Kevin
Frisch, Andrew T.
Dean, Victoria
Philbin, Mary
Cillo, Anthony R. https://orcid.org/0000-0002-3213-3129
Gingras, Sebastian https://orcid.org/0000-0003-2607-8642
Poholek, Amanda C. https://orcid.org/0000-0002-5587-8940
Kane, Lawrence P. https://orcid.org/0000-0001-5198-516X
Rivadeneira, Dayana B. https://orcid.org/0000-0001-9483-7036
Delgoffe, Greg M. https://orcid.org/0000-0002-2957-8135
- License Information
-
More Information
Article History
Received: 12 December 2023
Accepted: 2 October 2024
First Online: 8 November 2024
Competing interests
: G.M.D. and R.M.P. declare competing financial interests and have submitted patents (US patents: 63/223,473 and 63/223,453) for antibody targeting of MCT11 expressing T<sub>ex</sub> cells that and are entitled to a share in net income generated from licensing of these patent rights for commercial development. G.M.D. consults for and/or is on the scientific advisory board of BlueSphere Bio, Century Therapeutics, Nanna Therapeutics, Novasenta, Pieris Pharmaceuticals and Western Oncolytics/Kalivir and has grants from bluebird bio, Novasenta, Pfizer, Pieris Pharmaceuticals, TCR2 and Western Oncolytics/Kalivir. G.M.D. owns stock in Novasenta, BlueSphere Bio and RemplirBio. The other authors declare no competing interests.
